Moderna, Inc.
- Last sale
- Nov 12, 2026 · -6.97%
- Market cap
- $93.61B
- 404.62M shares
- Filings
- 1,053
Q3 2026−39.9% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026+34.7% FY25 yoy
- $93.61B
- —
- 37.1×
- 13.7×
- -2.10%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $1,944,000,000 | reported | |
| FY 2024 | 2024-12-31 | $3,236,000,000 | reported | |
| FY 2023 | 2023-12-31 | $6,848,000,000 | reported | |
| FY 2022 | 2022-12-31 | $19,263,000,000 | reported | |
| FY 2021 | 2021-12-31 | $18,471,000,000 | reported | |
| FY 2020 | 2020-12-31 | $803,000,000 | reported | |
| FY 2019 | 2019-12-31 | $60,209,000 revised | reported | |
| FY 2018 | 2018-12-31 | $135,068,000 | reported | |
| FY 2017 | 2017-12-31 | $205,825,000 | reported | |
| FY 2016 | 2016-12-31 | $108,396,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | $2.00M | $2.00M | — | 394.94M sh | +2.4% | — |
| FY2024 | — | $0.00 | $0.00 | — | 385.82M sh | +1.0% | — |
| FY2023 | — | $1.15B | $1.15B | — | 382.07M sh | −1.1% | — |
| FY2022 | — | $3.33B | $3.33B | — | 386.34M sh | −4.1% | 72.7% |
| FY2021 | — | $857.00M | $857.00M | — | 402.87M sh | +0.8% | 6.4% |
Segments
LineFY2022ShareChange
Rest of world$7.30B38%+34.0%
Europe$6.82B35%−0.5%
United States$5.15B27%−16.6%
Rest of world———
Total$19.26B
Biological products, except diagnostic substances
Moderna, Inc. is the 7th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
NBIXNeurocrine Biosciences Inc$2.9B21.4%16.7%$17.1BEXELExelixis, Inc.$2.3B7.0%33.7%$17.0BQGENQiagen N.V.$2.1B5.7%20.3%$10.9B
MRNAModerna, Inc. (this company)$1.9B39.9%145.2%$93.6B
HALOHalozyme Therapeutics, Inc.$1.4B37.6%22.7%$11.5BTECHBio-Techne Corp$1.2B0.4%15.0%$11.4BNVAXNovavax Inc$1.1B64.7%39.2%$1.4BBCRXBiocryst Pharmaceuticals Inc$874.8M94.1%30.2%$2.0BRGENRepligen Corp$738.3M16.4%6.6%$10.7BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Moderna, Inc. · CIK 1682852 · Engraved from SEC EDGAR